Lupin’s arm receives USFDA approval for generic Rifadin capsules

24 Aug 2013 Evaluate

Lupin’s - US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Rifampin Capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (USFDA).

Lupin’s Rifampin Capsules USP, 150 mg and 300 mg are the AB?rated generic equivalent of Sanofi Aventis’ Rifadin Capsules 150 mg and 300 mg strengths. Rifampin Capsules is indicated for the treatment of all forms of Tuberculosis and for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx.

Rifadin Capsules had annual US sales of approximately $18.5 million, as per IMS MAT March 2013. Lupin is one of the pioneers in the fight against Tuberculosis and holds global leadership positions in the Anti?TB segment.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×